A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab (MSB0010718C) in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer

Trial Profile

A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab (MSB0010718C) in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs Avelumab (Primary) ; Paracetamol
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 According to trial design presented at 53rd Annual Meeting of the American Society of Clinical Oncology, as of 16 patients have been enrolled, 13 on the MSS cohort and 3 on the MSI/POLE cohort.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 27 Feb 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top